Business
ESMO data highlights unique benefit of EpiSwitch
ESMO data highlights unique benefit of EpiSwitch.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n Podium presentation at ESMO highlights unique benefit\nof OBD's EpiSwitch® platform\n \n \n \n \n \n \n \n \n · \n \n Prof Thomas Powles, Director of Barts Cancer Centre, presented compelling data at ESMO'22 highlighting benefits of EpiSwitch® testing for predicting response to cancer checkpoint inhibitor therapy\n \n \n \n ·\n \n Study co-authored with Pfizer and five global medical centers\n \n \n \n ·\n \n Substantial interest in OBD's EpiSwitch Checkpoint inhibitor Response Test (CiRT) from oncologists, private insurers, as well as major pharma at the meeting\n \n \n \n ·\n \n EpiSwitch CiRT is already in clinical use in the UK and US\n \n \n \n · \n \n Healthcare systems could achieve significant savings by avoiding or reducing administration rate of ineffective ICI treatments through personalized testing with CiRT\n \n \n \n \n \n \n \n Oxford, UK - 15 September, 2022\n \n -\n Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces that its flagship EpiSwitch clinical platform was highlighted in a high-profile\n \n late-breaking podium presentation\n \n at the European Society of Medical Oncology (ESMO) Congress 2022, in Paris, France.\n \n \n In the presentation, co-authored with Pfizer, renowned oncology expert Prof Thomas Powles (Director, Barts Cancer Centre) highlighted the benefits to clinical practice of including EpiSwitch blood testing when\n predicting treatment response to avelumab, a leading immune checkpoint inhibitor (ICI).\n \n \n \"We looked at EpiSwitch markers in the blood of almost 500 patients from the JAVELIN 100 clinical study. Exploratory work with EpiSwitch testing could pick out patients who would respond to checkpoint inhibitors that conventional tumor mutational burden [TMB] testing did not identify,\" said Professor Powles. \"What is exciting is that the EpiSwitch platform enables us to do this from blood, rather than traditional methods which require an invasive tissue biopsy from the tumor.\"\n \n \n Pfizer's \n \n JAVELIN 100 trial\n \n was a multicenter, multinational, randomized, open-label, parallel-arm clinical trial that examined avelumab plus the best supportive care (BSC) versus BSC alone in patients with advanced urothe...